Anetumab Ravtansine
Sponsors
National Cancer Institute (NCI), Yale University, Mayo Clinic
Conditions
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaLung NeoplasmsMesothelin PositiveOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPancreatic AdenocarcinomaPancreatic Cancer
Phase 1
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Active, not recruitingNCT03126630
Start: 2018-10-04End: 2027-02-25Updated: 2026-04-01
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
TerminatedNCT03455556
Start: 2018-08-10End: 2020-01-07Updated: 2023-01-06
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
Active, not recruitingNCT03816358
Start: 2019-12-09End: 2027-01-31Target: 74Updated: 2026-07-21
Phase 2
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
TerminatedNCT02839681
Start: 2016-07-19End: 2018-07-25Updated: 2019-05-21
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
CompletedNCT03023722
Start: 2017-05-11End: 2019-12-11Updated: 2021-10-28
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruitingNCT03587311
Start: 2018-10-12End: 2026-10-21Target: 96Updated: 2026-07-08